The combination of lopinavir and ritonavir, HIV protease inhibitors, is one antiviral candidate for COVID-19. Lopinavir/ritonavir has exhibited some signs of effectiveness against severe acute respiratory syndrome (SARS). Lopinavir acts against the viral 3CL protease, and ritonavir increases drug bioavailability. Lopinavir/ritonavir is widely available and relatively easy to scale.
You must be logged in to reply to this topic.
For comments and inquiries about the COVID-19 Pharmacology Resource Center, please fill out the Contact Us form, and we will be in touch shortly.